Penn Pharma Further Expands Capabilities with Contained Roller Compaction Technology
![](/46/pdcnewsitem/03/42/53/UqMda0YXacAQAzj.jpg)
Pharmaceutical manufacturer, Penn Pharma has invested in a contained Gerteis Mini-Pactor further expanding its service offering at its world leading solid dose contained manufacturing facility at the Tredegar site in South Wales.
Penn Pharma has 20 years of experience in the use of roller compactor technology for pharmaceutical manufacturing and as a company, understands the importance of applying this valuable technology to address specific technical challenges.
The contained roller compactor will increase Penn’s ability to provide additional solutions for growing market demand for the processing and manufacturing of solid dosage forms containing potent molecules.
Roller compaction is a process that provides a granulation method for materials that are heat and moisture sensitive. It avoids the use of liquid and high temperatures associated with wet granulation and subsequent drying methods. The Gerteis Mini-Pactor offers a patented proven design that enhances powder flow as well as effective containment using skan isolator technology and integrated cleaning systems. The process is easily scaleable facilitating shorter and less costly development programmes.
The contained Gerteis Mini-Pactor roller compactor is a valuable addition to Penn’s vision of becoming the partner of choice for the development and manufacture of solid oral dose forms of highly potent products.
Mark Dean-Netscher, Vice President of International Operations at Penn Pharma said: “Our contained manufacturing facility is world class and additional investment in roller compaction capacity allows us to offer even more development and manufacturing solutions to our customers.”
Mark continued: “We have recognised and responded to a growing need within the industry for continuous granulation methods by developing our dry granulation capabilities. This roller compactor can be used from 1 kg development scale up to 100 kg per hour at production scale, without the need for additional scale up work. This will significantly reduce our clients’ costs and allow products to be developed and delivered to market far quicker.”
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance